Affinity maturation of tacrolimus antibody for improved immunoassay performance

Clinical Chemistry

Volumn 54, Issue 6, 2008, Pages 1008-1017

  Siegel, Robert W ^a,b   Baugher, Wade ^a   Rahn, Tanya ^a   Drengler, Susan ^a   Tyner, Joan ^a  

^a ABBOTT LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHANOL; ORGANIC SOLVENT; RECOMBINANT ANTIBODY; TACROLIMUS;

ANALYTIC METHOD; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ARTICLE; BLOOD SAMPLING; CLONE; DISSOCIATION CONSTANT; GENE MUTATION; IMMUNOASSAY; IN VITRO SELECTION; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TECHNOLOGY;

ANIMALS; ANTIBODY AFFINITY; CELL LINE; COMPLEMENTARITY DETERMINING REGIONS; HUMANS; HYBRIDOMAS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOSUPPRESSIVE AGENTS; MICE; MUTATION; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; TACROLIMUS;

EID: 44849121670     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.097352     Document Type: Article

References (30)

1. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256-65.
2. Fung JJ, Starzl TE. FK506 in solid organ transplantation. Ther Drug Monit 1995;17:592-5.
3. Inamura N, Nakahara K, Kino T, Goto T, Aoki H, Yamaguchi I, et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation 1988;45:206-9.
4. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature (Lond) 1991;352:803-7.
5. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993;17:60-8.
6. Dietemann J, Berthoux P, Gay-Montchamp JP, Batie M, Berthoux F. Comparison of ELISA method versus MEIA method for daily practice in the therapeutic monitoring of tacrolimus. Nephrol Dial Transplant 2001;16:2246-9.
7. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science (Wash DC) 1991;252:839-42.
8. Melnikova YI, Odintsov SG, Kravchuk ZI, Martsev SP. Antigen-binding activity of monoclonal antibodies after incubation with organic solvents. Biochemistry (Mosc) 2000;65:1256-65.
9. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997;15:553-7.
10. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 2000;97:10701-5.
11. Graff CP, Chester K, Begent R, Wittrup KD. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel 2004;17:293-304.
12. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 2005;351:158-69.
13. Weaver-Feldhaus JM, Miller KD, Feldhaus MJ, Siegel RW. Directed evolution for the development of conformation-specific affinity reagents using yeast display. Protein Eng Des Sel 2005;18:527-36.
14. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007;25:107-16.
15. Boder ET, Wittrup KD. Optimal screening of surface-displayed polypeptide libraries. Biotechnol Prog 1998;14:55-62.
16. Siegel RW, Coleman JR, Miller KD, Feldhaus MJ. High efficiency recovery and epitope-specific sorting of an scFv yeast display library. J Immunol Methods 2004;286:141-53.
17. VanAntwerp JJ, Wittrup KD. Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnol Prog 2000;16:31-7.
18. Gietz RD, Woods RA. Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 2006;313:107-20.
19. Boder ET, Wittrup KD. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 2000;328:430-44.
20. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006;1:755-68.
21. Orr-Weaver TL, Szostak JW, Rothstein RJ. Genetic applications of yeast transformation with linear and gapped plasmids. Methods Enzymol 1983;101:228-45.
22. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990;18:5322.
23. Darling RJ, Brault PA. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev Technol 2004;2:647-57.
24. Giudicelli V, Chaume D, Lefranc MP. IMGT/VQUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 2004;32:W435-40.
25. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997;273:927-48.
26. Groves M, Lane S, Douthwaite J, Lowne D, Gareth Rees D, Edwards B, Jackson RH. Affinity maturation of phage display antibody populations using ribosome display. J Immunol Methods 2006;313:129-39.
27. Luginbuhl B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, Cohen FE, et al. Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 2006;363:75-97.
28. Wang Z, Kim GB, Woo JH, Liu YY, Mathias A, Stavrou S, Neville DM. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv. Bioconjug Chem 2007;18:947-55.
29. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007;368:652-65.
30. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007;369:1015-28.